Abstract 10P
Interleukin-24 (IL-24) is known to selectively induce apoptosis in cancer cells through endoplasmic reticulum (ER) stress when it is expressed inside the cells. However, IL-24 alone is unable to enter the cells and consequently unable to inhibit cell proliferation. In the present study, we developed a novel chimeric protein, P28-IL-24, containing IL-24 which is linked to P-28, a defined cancer specific cell penetrating peptide and a P53 stabilizer, to target IL-24 into breast cancer cells. Afterwards, specific and non-specific cytolethal effect of this fusion protein were evaluated in vitro and in vivo.
Resources from the same session
The exosomes transfer the acquired resistance of MCF-7 breast cancer cells to rapamycin and tamoxifen
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract
The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
Presenter: Ludovic Bourre
Session: Poster Display & Cocktail
Resources:
Abstract
The CellMiner and CellMinerCDB web-applications as a base for pharmacogenomics
Presenter: William Reinhold
Session: Poster Display & Cocktail
Resources:
Abstract
The application of radiomics-based machine learning in the differential diagnosis between atypical low-grade astrocytoma and anaplastic astrocytoma
Presenter: Manni Wang
Session: Poster Display & Cocktail
Resources:
Abstract
Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacogenomics of docetaxel response in prostate cancer: A precision medicine initiative
Presenter: Abhinav Grover
Session: Poster Display & Cocktail
Resources:
Abstract
OX401, a new generation of PARP-interfering drug for cancer treatment
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract
Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract